BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthrough Potential

TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1% six-month response durability rate at its target dose. BeOne’s lung cancer ADC delivers a 56% response rate in CEA-high tumor patients. PRMT5 inhibitor BGB-58067 records 30.8% intracranial responses in lung cancer. ONC shares slip 1.21% [...]

The post BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthrough Potential appeared first on Blockonomi.